Protocol to identify small-molecule inhibitors against cancer drug resistance.

STAR protocols [STAR Protoc] 2025 Mar 21; Vol. 6 (1), pp. 103605. Date of Electronic Publication: 2025 Jan 30.

Competing Interests: Declaration of interests The authors declare no competing interests.
Drug resistance has emerged as a critical challenge in clinical cancer treatment. Here, we present a high-throughput screening protocol to identify therapeutic small-molecule inhibitors against drug-resistant cancer cells. We detail the steps for constructing drug-resistant cell models, executing the chemical screening process, and performing data analysis and validation. This protocol facilitates the rapid identification of therapeutic strategies for different types of drug-resistant cancers and aids in studying mechanisms. For complete details on the use and execution of this protocol, please refer to Zhang et al. ¹ .
(Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.)

English

Publisher: Cell Press Country of Publication: United States NLM ID: 101769501 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-1667 (Electronic) Linking ISSN: 26661667 NLM ISO Abbreviation: STAR Protoc Subsets: MEDLINE

Drug Resistance, Neoplasm*/drug effects , Small Molecule Libraries*/pharmacology , Antineoplastic Agents*/pharmacology , High-Throughput Screening Assays*/methods , Neoplasms*/drug therapy, Humans ; Cell Line, Tumor ; Drug Screening Assays, Antitumor/methods

20250505